Frontlight ResearchEarly access
Active, not recruitingNo phase
Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System
Key facts
- Who runs it
- Pentax Medical
- Where
- Baltimore, Chapel Hill, Chicago, Cleveland, Danville, Manhasset, New York, Orange, Philadelphia, Rochester, and Sarasota, United StatesSee the 11 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people, planned
- Started
- Mar 2016
- Ended
- Dec 2025
- Type of study
- Interventional
- Treatments tested
- CryoBalloon Ablation System
- Record updated
- 13 January 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Low- or high-grade non-nodular, previously untreated ("treatment naïve") dysplastic BE, confirmed by histopathological analysis. If nodular BE or Intramuscosal Cancer (ImCA) is identified during patient screening, this may be treated with Endoscopic Mucosal Resection (EMR) ≥6 weeks prior to treatment under this protocol. If previous EMR was performed, follow-up endoscopy must be negative for nodular BE. Patients with ImCA must be at low risk for recurrence, confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion
- BE length ≤6cm excluding visible BE islands, and Prague Classification C ≥0 / M ≥1
- Older than 18 years of age at time of consent
- Operable per institution's standards
- Provides written informed consent on the approved informed consent form
- Willing and able to comply with study requirements for follow-up
Who cannot take part
- Esophageal stenosis/stricture preventing advancement of a therapeutic endoscope (patients may have the stenosis/stricture dilated and then be treated with CryoBalloon ablation under this protocol at a subsequent procedure ≥2 weeks later)
- Any endoscopically-visualized abnormalities such as ulcers, masses or nodules. Neoplastic nodules must first be treated with EMR ≥6 weeks prior to planned treatment under this protocol
- Prior distal esophagectomy
- History of esophageal cancer more extensive than T1a or not meeting criteria for low risk of recurrence (confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion)
- History of esophageal varices
- Any clinical or histological suspicion of esophageal adenocarcinoma invading into the submucosa by endoscopic mucosal resection (EMR), or confirmed T1a cancer with positive deep margin by EMR
- Life expectancy ≤3 years, as judged by the site investigator
- Non-dysplastic or indefinite for dysplasia BE, confirmed by histopathological analysis
- Symptomatic untreated strictures
- Large (>4cm) hiatal hernia
- Active esophagitis grade B or higher
- Severe medical comorbidities precluding endoscopy
- Uncontrolled coagulopathy
- Pregnant or planning to become pregnant during period of study participation
- Patient refuses or is unable to provide written informed consent
- General poor health, multiple co-morbidities placing the patient at risk or otherwise unsuitable for trial participation
Where in United States
- John HopkinsBaltimore, United States
- University of North Carolina School of MedicineChapel Hill, United States
- University of ChicagoChicago, United States
- University Hospitals Cleveland Medical Center*Cleveland, United States
- Geisinger Medical CenterDanville, United States
- Northwell HealthManhasset, United States
- New York Presbyterian Hospital-Columbia University Medical CenterNew York, United States
- UC IrvineOrange, United States
- Thomas Jefferson UniversityPhiladelphia, United States
- Mayo ClinicRochester, United States
- Sarasota Memorial HospitalSarasota, United States
About the trial
What the trial wants to find out
To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)
The group in the trial
- CryoBalloon Ablation SystemOther group
Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium
- Publications
- Durability of cryoballoon ablation for eradication of neoplastic Barrett's esophagus: a multicenter prospective cohort study (with video).Gastrointestinal endoscopy, 2026
- Multifocal Cryoballoon Ablation for Eradication of Barrett's Esophagus-Related Neoplasia: A Prospective Multicenter Clinical Trial.The American journal of gastroenterology, 2020
- Record updated
- 13 January 2025